In Becker muscular dystrophy (BMD), muscle weakness progresses relatively slowly, with a highly variable rate among patients. This complicates clinical trials, as clinically relevant changes are difficult to capture within the typical duration of a trial. Therefore, predictors for disease progression are needed. We assessed if temporal increase of fat fraction (FF) in BMD follows a sigmoidal trajectory and whether fat fraction at baseline (FFbase) could therefore predict FF increase after 2 years (Delta FF). Thereafter, for two different MR-based parameters, we tested the additional predictive value to FFbase. We used 3-T Dixon data from the upper and lower leg, and multiecho spinecho MRI and 7-T P-31 MRS datasets from the lower leg, acquir...
<div><p>Objective</p><p>A number of promising experimental therapies for Duchenne muscular dystrophy...
Introduction/Aims: Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are characte...
OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are em...
Objective To identify the best quantitative fat-water MRI biomarker for disease progression of leg m...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by mutations in th...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Introduction/Aims Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are character...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Objective: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are em...
OBJECTIVE: To identify the best quantitative fat-water MRI biomarker for disease progression of leg ...
Introduction/Aims Becker muscular dystrophy (BMD) is characterized by variable disease severity and ...
In this thesis we evaluated several MRI/S methods as outcome parameters to assess muscle pathology i...
The Jain Foundation COS of dysferlinopathy is an international study in genetically confirmed dysfer...
<div><p>Background</p><p>Outcome measures for clinical trials in neuromuscular diseases are typicall...
<div><p>Objective</p><p>A number of promising experimental therapies for Duchenne muscular dystrophy...
Introduction/Aims: Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are characte...
OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are em...
Objective To identify the best quantitative fat-water MRI biomarker for disease progression of leg m...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by mutations in th...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Introduction/Aims Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are character...
Quantitative MRI and MRS of muscle are increasingly being used to measure individual pathophysiologi...
Objective: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are em...
OBJECTIVE: To identify the best quantitative fat-water MRI biomarker for disease progression of leg ...
Introduction/Aims Becker muscular dystrophy (BMD) is characterized by variable disease severity and ...
In this thesis we evaluated several MRI/S methods as outcome parameters to assess muscle pathology i...
The Jain Foundation COS of dysferlinopathy is an international study in genetically confirmed dysfer...
<div><p>Background</p><p>Outcome measures for clinical trials in neuromuscular diseases are typicall...
<div><p>Objective</p><p>A number of promising experimental therapies for Duchenne muscular dystrophy...
Introduction/Aims: Duchenne and Becker muscular dystrophies (DMD and BMD, respectively) are characte...
OBJECTIVE: A number of promising experimental therapies for Duchenne muscular dystrophy (DMD) are em...